MedConAT ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 15.5% 13.0% 14.2% 14.7%  
Credit score (0-100)  0 12 17 14 14  
Credit rating  N/A BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 -8.2 -5.3 -5.8 -6.0  
EBITDA  0.0 -8.2 -5.3 -5.8 -6.0  
EBIT  0.0 -8.2 -5.3 -5.8 -6.0  
Pre-tax profit (PTP)  0.0 -9.1 -5.5 -5.8 -6.0  
Net earnings  0.0 -9.1 -5.5 -5.8 -6.0  
Pre-tax profit without non-rec. items  0.0 -9.1 -5.5 -5.8 -6.0  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 30.9 25.4 19.7 13.7  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 35.9 30.7 25.4 19.7  

Net Debt  0.0 -31.9 -26.7 -11.9 -15.7  
 
See the entire balance sheet

Volume 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -8.2 -5.3 -5.8 -6.0  
Gross profit growth  0.0% 0.0% 35.0% -8.2% -4.3%  
Employees  0 1 0 0 0  
Employee growth %  0.0% 0.0% -100.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 36 31 25 20  
Balance sheet change%  0.0% 0.0% -14.3% -17.3% -22.6%  
Added value  0.0 -8.2 -5.3 -5.8 -6.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -22.8% -16.0% -20.5% -26.6%  
ROI %  0.0% -26.5% -18.9% -25.5% -36.0%  
ROE %  0.0% -29.6% -19.4% -25.5% -36.0%  

Solidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 86.1% 82.7% 77.4% 69.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 389.9% 502.8% 207.2% 260.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 6.4 5.0 3.7 2.6  
Current Ratio  0.0 6.4 5.0 3.7 2.6  
Cash and cash equivalent  0.0 31.9 26.7 11.9 15.7  

Capital use efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 26.9 21.4 15.7 9.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 -8 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -8 0 0 0  
EBIT / employee  0 -8 0 0 0  
Net earnings / employee  0 -9 0 0 0